JP2009541373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541373A5 JP2009541373A5 JP2009516901A JP2009516901A JP2009541373A5 JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5 JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009516901 A JP2009516901 A JP 2009516901A JP 2009541373 A5 JP2009541373 A5 JP 2009541373A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- adjuvant
- peptide
- protein
- vaccine according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 3
- 208000017667 Chronic Disease Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 230000006337 proteolytic cleavage Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600861 | 2006-06-28 | ||
| DKPA200600861 | 2006-06-28 | ||
| PCT/DK2007/000312 WO2008000261A2 (en) | 2006-06-28 | 2007-06-26 | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541373A JP2009541373A (ja) | 2009-11-26 |
| JP2009541373A5 true JP2009541373A5 (cg-RX-API-DMAC7.html) | 2010-07-29 |
| JP5165681B2 JP5165681B2 (ja) | 2013-03-21 |
Family
ID=38845996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009516901A Expired - Fee Related JP5165681B2 (ja) | 2006-06-28 | 2007-06-26 | タンパク質断片又はペプチドカクテルとして送達される抗原を用いたワクチン接種によるサブドミナントエピトープを含むｔ細胞レパートリーの拡大 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8105614B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2040745B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5165681B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090024292A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007264205B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0713978A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2654271A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2040745T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2400531T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2490024C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008000261A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000026248A2 (en) | 1998-11-04 | 2000-05-11 | Isis Innovation Limited | Tuberculosis diagnostic test |
| EP1523331B1 (en) * | 2002-07-13 | 2013-02-27 | Statens Serum Institut | Therapeutic tb vaccine |
| EP2160198A2 (en) * | 2007-05-31 | 2010-03-10 | Statens Serum Institut | Influenza vaccines |
| ES2394729T3 (es) * | 2007-06-29 | 2013-02-05 | Statens Serum Institut | El uso de monomicolil glicerol (MMG) como adyuvante |
| EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| AU2009253780B2 (en) | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| US20100015171A1 (en) | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
| WO2010060430A2 (en) * | 2008-11-28 | 2010-06-03 | Statens Serum Institut | Optimized influenza vaccines |
| EP2421557B1 (en) * | 2009-04-24 | 2018-12-05 | Statens Serum Institut | A tuberculosis tb vaccine to prevent reactivation |
| JP5600170B2 (ja) * | 2009-11-05 | 2014-10-01 | アメリカ合衆国 | Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍスポロゾイト及び肝臓段階抗原 |
| WO2011063133A1 (en) * | 2009-11-18 | 2011-05-26 | Auburn University | LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE |
| US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
| DK3079716T3 (da) * | 2013-12-13 | 2019-08-19 | Us Health | Multiepitop-tarp-peptidvaccine og anvendelser deraf. |
| BR112016023778A2 (pt) | 2014-04-24 | 2017-10-17 | Statens Seruminstitut | proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas |
| CN117064854A (zh) * | 2023-08-14 | 2023-11-17 | 广州谦毅生物医药有限公司 | 一种卡瓦脂质体的制备技术 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| US6641814B1 (en) * | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
| AU698878B2 (en) * | 1993-11-04 | 1998-11-12 | Genimmune N.V. | Immunodominant human T-cell epitopes of hepatitis C virus |
| CN1163602C (zh) * | 1998-04-07 | 2004-08-25 | 科里克萨公司 | 结核杆菌抗原融合蛋白及其应用 |
| US6649170B1 (en) * | 1999-05-12 | 2003-11-18 | Statens Serum Institut | Adjuvant combinations for immunization composition and vaccines |
| SE9903031D0 (sv) * | 1999-08-27 | 1999-08-27 | Eurodiagnostica Ab | Peptide mixture and vaccine against a chronic viral infection |
| EP1229931A4 (en) * | 1999-10-07 | 2003-05-28 | Corixa Corp | FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| IL152959A0 (en) | 2000-06-08 | 2003-06-24 | Intercell Biomedizinische Forschungs & Entwicklungs Gmbh | Immunostimulatory oligodeoxynucleotides |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| AU2003245729A1 (en) * | 2002-06-27 | 2004-01-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| US7749520B2 (en) * | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| WO2006002642A2 (en) | 2004-07-07 | 2006-01-12 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| FR2873467A1 (fr) | 2004-07-26 | 2006-01-27 | Proton World Internatinal Nv | Enregistrement d'une cle dans un circuit integre |
| EP2481423A1 (en) * | 2006-01-26 | 2012-08-01 | Pfizer Products Inc. | Novel glycolipid adjuvant compositions |
| GB0608368D0 (en) * | 2006-04-28 | 2006-06-07 | Isis Innovation | Process for making Oligopeptides |
-
2007
- 2007-06-26 EP EP07764444A patent/EP2040745B1/en not_active Not-in-force
- 2007-06-26 KR KR1020097001606A patent/KR20090024292A/ko not_active Ceased
- 2007-06-26 BR BRPI0713978-0A patent/BRPI0713978A2/pt not_active IP Right Cessation
- 2007-06-26 JP JP2009516901A patent/JP5165681B2/ja not_active Expired - Fee Related
- 2007-06-26 EP EP11182885A patent/EP2402024A1/en not_active Withdrawn
- 2007-06-26 CA CA002654271A patent/CA2654271A1/en not_active Abandoned
- 2007-06-26 ES ES07764444T patent/ES2400531T3/es active Active
- 2007-06-26 EP EP11182884A patent/EP2402023A1/en not_active Withdrawn
- 2007-06-26 WO PCT/DK2007/000312 patent/WO2008000261A2/en not_active Ceased
- 2007-06-26 AU AU2007264205A patent/AU2007264205B2/en not_active Expired - Fee Related
- 2007-06-26 RU RU2009102389/15A patent/RU2490024C2/ru not_active IP Right Cessation
- 2007-06-26 DK DK07764444.1T patent/DK2040745T3/da active
- 2007-06-27 US US11/823,402 patent/US8105614B2/en not_active Expired - Fee Related
-
2011
- 2011-12-16 US US13/328,319 patent/US20120156282A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541373A5 (cg-RX-API-DMAC7.html) | ||
| Kaur et al. | TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects | |
| US12070498B2 (en) | Conjugate vaccine targeting a disease-causing biological protein | |
| JP5654345B2 (ja) | 多量体マルチエピトープインフルエンザワクチン | |
| CN103747797B (zh) | 脂质体制剂 | |
| JP5775451B2 (ja) | インフルエンザを処置するための組成物および方法 | |
| EP2200638B1 (en) | Compositions for the transfection of cells | |
| RU2009102389A (ru) | Расширение спектра клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли | |
| JP2011512123A5 (cg-RX-API-DMAC7.html) | ||
| JP2011190278A (ja) | 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方 | |
| JP2011518179A5 (cg-RX-API-DMAC7.html) | ||
| JP2003531128A (ja) | 修飾ペプチドを含む医薬調製物 | |
| JP6158097B2 (ja) | 炎症を抑制するためのペプチド | |
| JP5766894B2 (ja) | ワクチン増強剤としてのαチモシンペプチド | |
| CN102088992B (zh) | 肽基二酰基甘油酯 | |
| Simerska et al. | Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines | |
| Yan et al. | Recent Advances in Liposome‐Based Nanoparticles for Antigen Delivery | |
| JP7050807B2 (ja) | 新規ペプチドベースのｐｃｓｋ９ワクチン | |
| WO2012147805A1 (ja) | 脳移行性機能性核酸及びその利用 | |
| JP2008531463A5 (cg-RX-API-DMAC7.html) | ||
| KR20090009839A (ko) | 면역조절 올리고펩티드 | |
| CN101336110B (zh) | 预防或治疗肝损伤的肽及其衍生物及其应用 | |
| RU2003110420A (ru) | Дифференцирование gnrh-i и gnrh-ii | |
| JPWO2000051634A1 (ja) | 脂肪酸を構成成分とするワクチン製剤 | |
| CN102178926A (zh) | 预防或治疗肝损伤的肽 |